Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 1-Year High – Here’s What Happened

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $17.20 and last traded at $16.67, with a volume of 704076 shares. The stock had previously closed at $16.55.

More Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Analysts have raised price targets and maintained buy interest—Citigroup and HC Wainwright lifted targets toward $20 and several firms maintain Buy/Strong-Buy views, supporting upside expectations versus peer biotech risk. Analyst Coverage Summary
• Neutral Sentiment: Institutional ownership is high (~95.8%), and the stock sits well above its 50- and 200-day moving averages — technicals and concentrated institutional positions can amplify moves but don’t by themselves resolve direction. Institutional Holdings Detail
• Negative Sentiment: CEO Joshua B. Cohen completed a large sale (136,193 shares on Jan. 15) for about $1.85M at roughly $13.59 — a meaningful reduction (~3.9%) of his holding that can be read as a near-term supply signal and is likely weighing on sentiment. SEC Filing: Joshua B. Cohen
• Negative Sentiment: Additional small executive sales were reported: Joshua Cohen sold 1,974 shares (avg. $13.83) and Justin Klee sold 1,995 shares (avg. $13.89) on Jan. 16 — these insider disposals (though small relative to total holdings) reinforce the headline of CEO selling activity. Justin Klee Sale Joshua Cohen Sale

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AMLX shares. Bank of America increased their price objective on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price target on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Amylyx Pharmaceuticals Stock Up 0.8%

The company has a market cap of $1.83 billion, a PE ratio of -9.28 and a beta of -0.31. The firm has a fifty day simple moving average of $13.17 and a 200-day simple moving average of $11.75.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. Equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In related news, CFO James M. Frates sold 3,326 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total transaction of $36,951.86. Following the transaction, the chief financial officer owned 177,104 shares of the company’s stock, valued at $1,967,625.44. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Joshua B. Cohen sold 136,193 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the sale, the chief executive officer directly owned 3,378,546 shares of the company’s stock, valued at approximately $45,914,440.14. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 157,783 shares of company stock worth $2,122,808 in the last three months. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Several hedge funds have recently modified their holdings of AMLX. Commodore Capital LP purchased a new stake in Amylyx Pharmaceuticals during the third quarter worth about $55,386,000. First Light Asset Management LLC purchased a new stake in Amylyx Pharmaceuticals during the third quarter worth $45,606,000. Adage Capital Partners GP L.L.C. boosted its position in Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after purchasing an additional 3,102,395 shares in the last quarter. Millennium Management LLC grew its holdings in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new position in shares of Amylyx Pharmaceuticals in the third quarter valued at $25,821,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.